Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Petros Pharmaceuticals Inc (PTPI)

Petros Pharmaceuticals Inc (PTPI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 19,456
  • Shares Outstanding, K 20,685
  • Annual Sales, $ 7,810 K
  • Annual Income, $ -8,990 K
  • 60-Month Beta 1.80
  • Price/Sales 2.26
  • Price/Cash Flow N/A
  • Price/Book 0.49
Trade PTPI with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.35
  • Most Recent Earnings -0.01 on 05/16/22
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 167.24% ( -8.15%)
  • Historical Volatility 118.42%
  • IV Percentile 36%
  • IV Rank 28.72%
  • IV High 409.30% on 12/27/21
  • IV Low 69.69% on 03/15/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 210
  • Volume Avg (30-Day) 89
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 1,944
  • Open Int (30-Day) 6,062

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6458 +45.65%
on 05/23/22
1.2200 -22.90%
on 05/03/22
-0.1894 (-16.76%)
since 04/27/22
3-Month
0.6458 +45.65%
on 05/23/22
1.7900 -47.45%
on 04/19/22
-0.4894 (-34.22%)
since 02/25/22
52-Week
0.6458 +45.65%
on 05/23/22
5.2000 -81.91%
on 11/29/21
-2.2194 (-70.23%)
since 05/27/21

Most Recent Stories

More News
Petros Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

NEW YORK, May 16, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (“Petros” or “the Company”) (Nasdaq: PTPI), a leading provider of therapeutics...

PTPI : 0.9406 (+10.30%)
Petros Pharmaceuticals to Pursue 505(B)(2) Pathway for H-100, Company’s Novel Topical Investigational Treatment for Peyronie’s Disease Which Impacts More Than 1 in 10 Men in the US

Company Is Developing H-100 as Potentially the First FDA-Approved, Nanoparticle-Based Topical Treatment Designed to Provide Improved and Sustained Local...

PTPI : 0.9406 (+10.30%)
Petros Pharmaceuticals to Present at the Planet MicroCap Showcase 2022

NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men’s health, announces...

PTPI : 0.9406 (+10.30%)
Keynotes, Educational Panels and 88 Companies to Present at the Planet MicroCap Showcase on May 3-5, 2022 at Bally's Hotel & Casino in Las Vegas, NV

LOS ANGELES, CA / ACCESSWIRE / April 27, 2022 / SNN Network presents the Planet MicroCap Showcase taking place on May 3-5, 2022, where 88 MicroCap public and private companies will be presenting at Bally's...

CHL.AX : 2.120 (-1.40%)
DCM : 25.60 (-1.35%)
DDDX : 0.0625 (+4.17%)
AAT.VN : 0.055 (unch)
AATGF : 0.0285 (-5.00%)
ASTR.VN : 0.200 (+14.29%)
AMI.VN : 0.345 (+1.47%)
AUUD : 1.0300 (+7.49%)
AYRO : 1.0400 (+4.00%)
BNXA.VN : 1.510 (-5.63%)
BNXAF : 1.2300 (-2.77%)
BICX : 2.5000 (+0.40%)
Petros Pharmaceuticals, Inc. Engages Massachusetts General Hospital in a Sponsored Research Agreement for Tissue-Specific Oxygenation Sensor Technology

Sensor Measures Oxygen Levels Within Specific Human Tissue, Potentially Allowing Biosensor Feedback of Erectile Device Therapy...

PTPI : 0.9406 (+10.30%)
Petros Pharmaceuticals Announces Positive Results of Over-the-Counter (OTC) Label Comprehension Study for Erectile Dysfunction Drug STENDRA (avanafil)

Clear Understanding of STENDRA OTC Label to be Key Element in OTC Development Program Company is Pursuing...

PTPI : 0.9406 (+10.30%)
Petros Pharmaceuticals Reports Year End 2021 Financial Results and Corporate Highlights

NEW YORK, April 01, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (“Petros” or “the Company”) (Nasdaq: PTPI), a leading provider of therapeutics...

PTPI : 0.9406 (+10.30%)
Petros Pharmaceuticals to Present at the Q1 Investor Summit Conference

NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men’s health, announces...

PTPI : 0.9406 (+10.30%)
Q4 Investor Summit Small Cap & Micro Cap Conference To Offer Opportunity to Meet with C-level Management of 90+ Companies

Small and Micro-cap investors are invited to attend the Q4 Investor Summit being held on November 16-17, 2021. The event is organized by the Investor Summit Group, recognised as a highly reputed brand...

AZ.TO : 6.19 (unch)
AAZZF : 10.8545 (+0.13%)
ACST : 0.9466 (+2.63%)
ATNM : 5.63 (+2.36%)
ADCO.TO : 0.2700 (unch)
ADCOF : 0.2145 (+2.14%)
ALIM : 5.72 (-1.38%)
ACOGF : 0.5549 (+0.89%)
AMST : 0.5791 (-0.91%)
ANVS : 10.13 (+10.83%)
ANPC : 0.2909 (+6.56%)
ARC : 3.09 (+3.69%)
Petros Pharmaceuticals to Participate at Upcoming Benzinga Conference and Interview Show

/PRNewswire/ -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, announces today that President and Chief...

PTPI : 0.9406 (+10.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Petros Pharmaceuticals Inc. is a men's health company. It engages in identifying, developing, acquiring, and commercializing innovative therapeutics for men's health issues including, endothelial dysfunction, psychosexual and psychosocial ailments, Peyronie's disease, hormone health and substance use...

See More

Key Turning Points

3rd Resistance Point 1.1304
2nd Resistance Point 1.0402
1st Resistance Point 0.9904
Last Price 0.9406
1st Support Level 0.8504
2nd Support Level 0.7602
3rd Support Level 0.7104

See More

52-Week High 5.2000
Fibonacci 61.8% 3.4603
Fibonacci 50% 2.9229
Fibonacci 38.2% 2.3855
Last Price 0.9406
52-Week Low 0.6458

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar